BACKGROUND: Inherited cardiac arrhythmia susceptibility contributes to sudden death during infancy and may contribute to perinatal and neonatal mortality, but the molecular basis of this risk and the relationship to genetic disorders presenting later in life is unclear. We studied the functional and pharmacological properties of a novel de novo cardiac sodium channel gene (SCN5A) mutation associated with an extremely severe perinatal presentation of long-QT syndrome in unrelated probands of different ethnicity. METHODS AND RESULTS: Two subjects exhibiting severe fetal and perinatal ventricular arrhythmias were screened for SCN5A mutations, and the functional properties of a novel missense mutation (G1631D) were determined by whole-cell patch clamp recording. In vitro electrophysiological studies revealed a profound defect in sodium channel function characterized by approximately 10-fold slowing of inactivation, increased persistent current, slowing of recovery from inactivation, and depolarized voltage dependence of activation and inactivation. Single-channel recordings demonstrated increased frequency of late openings, prolonged mean open time, and increased latency to first opening for the mutant. Subjects carrying this mutation responded clinically to the combination of mexiletine with propranolol and survived. Pharmacologically, the mutant exhibited 2-fold greater tonic and use-dependent mexiletine block than wild-type channels. The mutant also exhibited enhanced tonic (2.4-fold) and use-dependent block ( approximately 5-fold) by propranolol, and we observed additive effects of the 2 drugs on the mutant. CONCLUSIONS: Our study demonstrates the molecular basis for a malignant perinatal presentation of long-QT syndrome, illustrates novel functional and pharmacological properties of SCN5A-G1631D, which caused the disorder, and reveals therapeutic benefits of propranolol block of mutant sodium channels in this setting.
BACKGROUND: Inherited cardiac arrhythmia susceptibility contributes to sudden death during infancy and may contribute to perinatal and neonatal mortality, but the molecular basis of this risk and the relationship to genetic disorders presenting later in life is unclear. We studied the functional and pharmacological properties of a novel de novo cardiac sodium channel gene (SCN5A) mutation associated with an extremely severe perinatal presentation of long-QT syndrome in unrelated probands of different ethnicity. METHODS AND RESULTS: Two subjects exhibiting severe fetal and perinatal ventricular arrhythmias were screened for SCN5A mutations, and the functional properties of a novel missense mutation (G1631D) were determined by whole-cell patch clamp recording. In vitro electrophysiological studies revealed a profound defect in sodium channel function characterized by approximately 10-fold slowing of inactivation, increased persistent current, slowing of recovery from inactivation, and depolarized voltage dependence of activation and inactivation. Single-channel recordings demonstrated increased frequency of late openings, prolonged mean open time, and increased latency to first opening for the mutant. Subjects carrying this mutation responded clinically to the combination of mexiletine with propranolol and survived. Pharmacologically, the mutant exhibited 2-fold greater tonic and use-dependent mexiletine block than wild-type channels. The mutant also exhibited enhanced tonic (2.4-fold) and use-dependent block ( approximately 5-fold) by propranolol, and we observed additive effects of the 2 drugs on the mutant. CONCLUSIONS: Our study demonstrates the molecular basis for a malignant perinatal presentation of long-QT syndrome, illustrates novel functional and pharmacological properties of SCN5A-G1631D, which caused the disorder, and reveals therapeutic benefits of propranolol block of mutant sodium channels in this setting.
Authors: P J Schwartz; S G Priori; C Spazzolini; A J Moss; G M Vincent; C Napolitano; I Denjoy; P Guicheney; G Breithardt; M T Keating; J A Towbin; A H Beggs; P Brink; A A Wilde; L Toivonen; W Zareba; J L Robinson; K W Timothy; V Corfield; D Wattanasirichaigoon; C Corbett; W Haverkamp; E Schulze-Bahr; M H Lehmann; K Schwartz; P Coumel; R Bloise Journal: Circulation Date: 2001-01-02 Impact factor: 29.690
Authors: Ramon Brugada; Kui Hong; Robert Dumaine; Jonathan Cordeiro; Fiorenzo Gaita; Martin Borggrefe; Teresa M Menendez; Josep Brugada; Guido D Pollevick; Christian Wolpert; Elena Burashnikov; Kiyotaka Matsuo; Yue Sheng Wu; Alejandra Guerchicoff; Francesca Bianchi; Carla Giustetto; Rainer Schimpf; Pedro Brugada; Charles Antzelevitch Journal: Circulation Date: 2003-12-15 Impact factor: 29.690
Authors: Troy E Rhodes; Robert L Abraham; Richard C Welch; Carlos G Vanoye; Lia Crotti; Marianne Arnestad; Roberto Insolia; Matteo Pedrazzini; Chiara Ferrandi; Ashild Vege; Torleiv Rognum; Dan M Roden; Peter J Schwartz; Alfred L George Journal: J Mol Cell Cardiol Date: 2007-12-07 Impact factor: 5.000
Authors: John R Bankston; Minerva Yue; Wendy Chung; Meghan Spyres; Robert H Pass; Eric Silver; Kevin J Sampson; Robert S Kass Journal: PLoS One Date: 2007-12-05 Impact factor: 3.240
Authors: Lisa L Murphy; Anita J Moon-Grady; Bettina F Cuneo; Ronald T Wakai; Suhong Yu; Jennifer D Kunic; D Woodrow Benson; Alfred L George Journal: Heart Rhythm Date: 2011-11-07 Impact factor: 6.343
Authors: Haifa Hallaq; Dao W Wang; Jennifer D Kunic; Alfred L George; K Sam Wells; Katherine T Murray Journal: Am J Physiol Heart Circ Physiol Date: 2011-11-18 Impact factor: 4.733
Authors: Lia Crotti; Christopher N Johnson; Elisabeth Graf; Gaetano M De Ferrari; Bettina F Cuneo; Marc Ovadia; John Papagiannis; Michael D Feldkamp; Subodh G Rathi; Jennifer D Kunic; Matteo Pedrazzini; Thomas Wieland; Peter Lichtner; Britt-Maria Beckmann; Travis Clark; Christian Shaffer; D Woodrow Benson; Stefan Kääb; Thomas Meitinger; Tim M Strom; Walter J Chazin; Peter J Schwartz; Alfred L George Journal: Circulation Date: 2013-02-06 Impact factor: 29.690